Last reviewed · How we verify
Dextrotubocurarine Chloride (TUBOCURARINE)
Dextrotubocurarine Chloride, also known as TUBOCURARINE, is a non-depolarizing neuromuscular blocking agent developed by Bristol Myers Squibb in 1945. It works by competitively binding to the acetylcholine receptor, preventing acetylcholine from binding and causing muscle relaxation. TUBOCURARINE is used to relax muscles and is off-patent, meaning it is no longer protected by patents. As a result, there are no generic manufacturers of the drug. Key safety considerations include its potential to cause respiratory depression and prolonged paralysis.
At a glance
| Generic name | TUBOCURARINE |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | tubocurarine |
| Target | Acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1945 |
Approved indications
- Muscle relaxation, function
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextrotubocurarine Chloride CI brief — competitive landscape report
- Dextrotubocurarine Chloride updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI